Menarini Asia-Pacific strengthens men's health portfolio in China

New Drug Applications |  News | 0 Comment | 22 Jul, 2021

Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world's largest Italian biopharmaceutical comp...Read more

China supports global polio endgame strategy with new vaccine

New Drug Applications |  News | 0 Comment | 19 Jul, 2021

Sinovac Biotech, a leading provider of biopharmaceutical products in China, has received a drug registration approval fr...Read more

Frontier Biotechnologies launches two drug regimen for HIV

New Drug Applications |  News | 0 Comment | 19 Jul, 2021

In conjunction with the IAS Conference on HIV Science, Germany's Frontier Biotechnologies has announced positive top-lin...Read more

Eisai launches bile acid transporter inhibitor Goofice in Thailand

New Drug Applications |  News | 0 Comment | 19 Jul, 2021

Eisai's Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofic...Read more

Jardiance (empagliflozin) approved in Europe for the treatment of heart failure

New Drug Applications |  News | 0 Comment | 06 Jul, 2021

The European Commission has granted marketing authorization for Jardiance®(empagliflozin) as a treatment for adults ...Read more

Scientists propose repurposing anti-malarial drug Mefloquine to fight COVID-19

New Drug Applications |  News | 0 Comment | 02 Jul, 2021

Japanese scientists are scanning the possibility of using an anti-malarial drug called mefloquine....Read more

eTheRNA, VUB expand collaboration to engineer next-generation mRNA therapeutics

New Drug Applications |  News | 0 Comment | 23 Jun, 2021

eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and ...Read more

Vectura, Incannex to advance IHL-216A for treatment of traumatic brain injury

New Drug Applications |  News | 0 Comment | 22 Jun, 2021

Vectura Group has signed an agreement with Australia-based Incannex Healthcare to provide pre-clinical development servi...Read more

RSF Bio enters worldwide license agreement with Sanofi for cardiovascular drug

New Drug Applications |  News | 0 Comment | 18 Jun, 2021

Rancho Santa Fe Bio, Inc. (RSF Bio), a San Diego, California-based clinical-stage cardiovascular platform company, annou...Read more

Merck to commercialize Type 2 Diabetes drug in six growth markets

New Drug Applications |  News | 0 Comment | 04 May, 2021

Merck has signed a collaboration agreement with Janssen Pharmaceuticals NV around the commercialization of INVOKANA...Read more

S. Korea's Peptron licenses global development of ADCs for cancer treatment

New Drug Applications |  News | 0 Comment | 19 Apr, 2021

Peptron, Inc., a South Korea-based biotech company, and Qilu Pharmaceutical, a China-based pharmaceutical company f...Read more

BioVersys receives €20M in EU financing to support new antibiotics development

New Drug Applications |  News | 0 Comment | 14 Apr, 2021

The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments ...Read more

SK Biopharma seizures/epilepsy drug to launch in Europe

New Drug Applications |  News | 0 Comment | 05 Apr, 2021

SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced that cenobamate received marketi...Read more

Australian oncology drug Paxalisib receives rights to develop and commercialize in China

New Drug Applications |  News | 0 Comment | 05 Apr, 2021

Sydney-based Kazia Therapeutics Limited, an oncology-focused drug development company announced that it has entered into...Read more

Astellas launches XOSPATA (gilteritinib) in Singapore to treat adult Leukaemia patients

New Drug Applications |  News | 0 Comment | 31 Mar, 2021

Astellas Pharma Inc. announced on March 31, 2021, that XOSPATA® (generic name: gilteritinib) is now available for pr...Read more

Eisai's Anti Cancer agent Lenvatinib-Pembrolizumab combo receives EMA in Japan

New Drug Applications |  News | 0 Comment | 30 Mar, 2021

Eisai Co., Ltd. announced on March 30, 2021 that the European Medicines Agency (EMA) has confirmed it has acce...Read more

EirGenix's proposed Biosimilar 'Trastuzumab' shows positive Ph 3 results

New Drug Applications |  News | 0 Comment | 25 Mar, 2021

EirGenix, Inc. announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimi...Read more

Eisai Medicine Innovation Technology Solutions to launch in Japan

New Drug Applications |  News | 0 Comment | 22 Mar, 2021

Japanese firm Eisai Co., Ltd. as part of its strategic investment to realize its medium-term management plan, EWAY ...Read more